Use this field to search all clinical research documents.
Clinical Research Resources & Offices
DF/HCC has one of the largest clinical research initiatives in the country, taking a unified approach to approving, activating, monitoring, and supporting the cancer-related clinical trials conducted at our member institutions. For more information, please take a moment to review the functions of each of the 3 distinct clinical research offices below, and continue on to the appropriate destination.
For your convenience there are many ways to find the Policies, Guidance, Forms, Templates, and Resources that you may be looking for. Expand the 'CRS Introduction' section for a walkthrough, or head to one of DF/HCC's three clinical research offices below.
View resources that may be helpful within the Clinical Research Support section of the DF/HCC website.
New to clinical research at DF/HCC, or need a refresher on where to find certain resources? View the New PI and Staff page for more information or for support.
Clinical Research at Dana-Farber/Harvard Cancer Center member institutions is facilitated by way of a unified clinical research effort across all member institutions. There are three offices responsible for coordinating this unified effort: The Research Informatics Operations (RIO), The Office of Data Quality (ODQ), and The Office for Human Research Studies (OHRS).
Although all documents are available in a centralized place via the Protocol Lifecycle, or the Document Library, support for specific clinical research areas, functions, or software used across the Cancer Center can be attained by visiting the corresponding office page. View the common functions for each office below.
The DFCI IRB has acknowledged a nationwide shortage of Diphenhydramine Injection (IV Benadryl) and has determined that the shortage is not considered serious or continuing non-compliance or an unanticipated problem...
December 04, 2018
– Office for Human Research Studies
In 2017, the FDA announced that they have further streamlined the expanded access process by updating the Form 3926 to allow for a waiver of the requirement for review and approval at a convened IRB meeting. As a...